Nika Pharmaceuticals, Inc SEC filings NIKA
Nika Pharmaceuticals, Inc has 71 filings in SEC EDGAR's recent list, going back to Dec 3, 2020. Its latest annual report, Form 10-K, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2024 (auditor change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 25, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 7, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 144 | Notice of proposed sale | Apr 16, 2025 | — |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| 4 | Insider transaction | Mar 19, 2025 | Mar 18, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 10-Q/A | Amended quarterly report | Nov 1, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Auditor change
|
Oct 16, 2024 | Oct 2, 2024 |
| UPLOAD | Letter from the SEC | Oct 8, 2024 | — |
| 8-K |
Current report
Auditor change
|
Oct 1, 2024 | Sep 23, 2024 |
| RW | Form rw | Sep 19, 2024 | — |
| 10-Q | Quarterly report | Sep 18, 2024 | Jun 30, 2024 |
| RW | Form-rw | Sep 16, 2024 | — |
| RW | Filing | Sep 12, 2024 | — |
| 8-K |
Current report
Acquisition or sale of assets
|
Aug 27, 2024 | Aug 18, 2024 |
| NT 10-Q | From 12b-25 | Aug 14, 2024 | Jun 30, 2024 |
| CORRESP | Letter to the SEC | Jun 24, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2024 | — |
| 10-Q | Quarterly report | May 28, 2024 | Mar 31, 2024 |
| NT 10-Q | Form 12b-25 | May 16, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Acquisition or sale of assets, Other events
|
May 10, 2024 | Apr 23, 2024 |
| CORRESP | Letter to the SEC | May 9, 2024 | — |
| UPLOAD | Letter from the SEC | May 2, 2024 | — |
| 8-K |
Current report
Acquisition or sale of assets
|
Apr 15, 2024 | Apr 10, 2024 |
| S-4/A | Form s-4/a | Apr 5, 2024 | — |
| 10-K | Annual report | Apr 1, 2024 | Dec 31, 2023 |
| 4 | Insider transaction | Mar 19, 2024 | Apr 29, 2022 |
| 4 | Insider transaction | Mar 19, 2024 | Apr 13, 2022 |
| DEL AM | Form del am | Mar 8, 2024 | — |
| S-4 | Registration for a merger or exchange | Mar 6, 2024 | — |
| 8-K |
Current report
Acquisition or sale of assets, Bylaw or fiscal year change
|
Mar 5, 2024 | Mar 1, 2024 |
| 8-K |
Current report
Auditor change
|
Feb 16, 2024 | Feb 14, 2024 |
| 10-Q | Quarterly report | Oct 31, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control
|
Sep 18, 2023 | Sep 18, 2023 |
| 10-Q | Quarterly report | Aug 21, 2023 | Jun 30, 2023 |
| NT 10-Q | Form nt 10-q | Aug 14, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 10-K | Annual report | Apr 10, 2023 | Dec 31, 2022 |
| NT 10-K | Form nt 10-k | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Nov 15, 2022 | Nov 12, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 10-Q/A | Amended quarterly report | Nov 7, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Auditor change
|
Nov 1, 2022 | Oct 31, 2022 |
| 10-Q | Quarterly report | Aug 22, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 22, 2022 | Aug 22, 2022 |
| NT 10-Q | Form nt 10-q | Aug 15, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Acquisition or sale of assets, Change to shareholder rights
|
Apr 12, 2022 | Apr 12, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 5, 2022 | Apr 5, 2022 |
| 10-K | Annual report | Mar 3, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 11, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 13, 2021 | Mar 31, 2021 |
| 10-K/A | Amended annual report | Mar 25, 2021 | Dec 31, 2020 |
| 10-K | Annual report | Mar 24, 2021 | Dec 31, 2020 |
| UPLOAD | Letter from the SEC | Jan 22, 2021 | — |
| 10-12G/A | Form 10-12g/a | Jan 21, 2021 | — |
| 10-12G/A | Form 10-12g/a | Jan 21, 2021 | — |
| CORRESP | Letter to the SEC | Jan 20, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2021 | — |
| RW | Filing | Dec 30, 2020 | — |
| RW WD | Filing | Dec 29, 2020 | — |
| RW | Filing | Dec 29, 2020 | — |
| 10-12G | Form 10-12g | Dec 28, 2020 | — |
| 1-A-W | Form aw | Dec 23, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2020 | — |
| 10-12B | Form 10-12b | Dec 3, 2020 | — |
Showing 71 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NIKA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CO
- Headquarters
- Henderson, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1145604
- Former names
- CENTENNIAL GROWTH EQUITIES INC (until Aug 15, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.